AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04234971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intervention group (DBM/BMP)
Description: All patients will undergo a standard procedure for exposure of the cleft alveolar defect and closure of all oronasal fistulae. After induction of general anesthesia, the patient will be intubated with an oral ray tube and prepped and draped in sterile fashion. Pre-operative antibiotics will be given to cover oral flora (i.e. Unasyn or clindamycin if penicillin allergy exists). The intra-oral space will be exposed and the nasal floor and palatal mucosa will be primarily closed to create a water-tight space for the graft. The integrity of the nasal floor mucosa will be tested using methylene blue dye. Following closure of the fistula, the alveolar bone graft will be performed. For the treatment group, 10cc of crushed DBM will be mixed with the micro-sized sponge of rh-BMP-2 (Infuse Bone Graft, Medronic, Minneapolis, MN). The sponge and DBM will then be packed into the defect to completely fill the bony space (FIGURE 3). The anterior mucosa will then be closed.
Study NCT06239246 — intervention group
Intervention type: OTHER
Intervention: Behavioral
Description: Psychotherapy: Cognitive-behavioral therapy (CBT), Internet-based cognitive-behavioral therapy (I-CBT), cognitive-behavioral therapy for insomnia (CBT-I), self-management education for heart failure, blended intervention; Drug treatment (cardiovascular drugs: aspirin, clopidogrel, ticagrelor, statins; psychiatric drugs: SSRIs, SNRIs, etc.);
Study NCT05290987 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nasal spray
Description: 2 sprays in each nostril, 6 times a day
Study NCT05290987 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: nasal spray
Description: 2 sprays in each nostril, 6 times a day
Study NCT04234971 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control group(autologous ICBG)
Description: The patient will be induced with anesthesia, prepped, and draped. The intra-oral space will be exposed and the nasal floor and palatal mucosa will be primarily closed to create a water-tight space for the graft. The integrity of the nasal floor mucosa will be tested using methylene blue dye. Following closure of the fistula, the alveolar bone graft will be performed.In the control group, the ICBG will be harvested percutaneously using the Accumed bone graft harvesting system. Briefly, an incision will be made in iliac crest and drill bit inserted. Multiple passes of the drill be used to harvest as much autograft bone as possible from the cancellous region of the iliac crest.Following harvest, fibrin glue will be instilled for hemostasis and a Ropivicaine On-Q pain pump inserted for post-operative pain control. The harvest bone graft will be packed into the alveolar defect in a similar fashion and the mucosa closed anteriorly.
Study NCT05683574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDC of etoricoxib + cyclobenzaprine + etoricoxib placebo
Description: Participants randomized to this group will receive one (01) capsule of the investigational drug and one (01) etoricoxib placebo tablet, respecting a minimum interval of twenty-four (24) hours between doses for 3 days.
Study NCT05683574 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etoricoxib 90 mg (Arcoxia®) +FDC placebo
Description: Participants randomized to this group will receive one (01) etoricoxib 90 mg tablet (Arcoxia®) and one (01) FDC placebo capsule, respecting a minimum interval of twenty-four (24) hours between doses for 3 days.
Study NCT05683574 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclobenzaprine hydrochloride + etoricoxib placebo
Description: Participants randomized to this group will receive one (01) cyclobenzaprine hydrochloride 15 mg capsule (XL - Mitrul®) and one (01) etoricoxib placebo tablet, respecting a minimum interval of twenty-four (24) hours between doses for 3 days.
Study NCT04857437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07202954 Repeat Dose
Description: 10, 30, 100, 300, 600, 1200 milligrams (mg)
Study NCT04857437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07202954 Single Dose
Description: 10, 30, 100, 300, 600, 900, 1200 milligrams (mg)
Study NCT04857437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo
Study NCT06542120 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Heart Auscultation and Echocardiography
Description: Heart auscultation will be done by pediatrician and echocardiography by echocardiologist
Study NCT01027338 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tai chi exercise
Study NCT06542120 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Chest Auscultation and Chest imaging examinations
Description: Chest auscultation will be done by pediatrician and chest imaging examinations by radiologist
Study NCT06542120 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Abdominal Auscultation and Abdominal imaging examinations
Description: Abdominal auscultation will be done by pediatrician and chest imaging examinations by radiologist
Study NCT06336460 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pericapsular Nerve Group (PENG) Block
Description: Under sterile technique, physician will identify relevant landmarks including the femoral artery, femoral vein, femoral nerve, ileopubic eminence (IPE), anterior inferior iliac spine (AIIS), psoas tendon (PT). Target area is bony space between AIIS and IPE adjacent to PT.~Using in-plane technique with constant visualization, needle will be inserted through skin and soft tissue targeting fascial plane below the psoas tendon, above ilium bone. Landmark lies between the AIIS and IPE, just lateral to psoas tendon.~As needle tip reaches target, small volume of normal saline will be injected to hydrodissect tissue. Fluid will start to spread along fascial plane, lifting the psoas tendon from ilium, confirming proper positioning.~Normal saline will then be switched to anesthetic (30mL of Bupivacaine 0.25%).~After full volume of anesthetic has been injected, a small volume (5mL) of normal saline will be injected to flush line of remaining anesthetic. Needle will then be withdrawn.
Study NCT06336460 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fascia Iliaca Compartment (FIC) Block for Patients with Isolated Hip Fractures
Description: Under sterile technique, physician will identify relevant landmarks, including femoral artery, femoral vein, femoral nerve, iliacus muscle with overlying fascia iliaca.~Using in-plane technique with constant visualization, needle will be inserted through skin and soft tissue targeting the fascial plane above iliacus muscle.~As needle tip reaches the target, a small volume of normal saline will be injected to hydrodissect tissue. Fluid will start to spread along fascial plane, confirming proper positioning.~Normal saline will then be switched to anesthetic (30mL of Bupivacaine 0.25%).~After full volume of anesthetic has been injected, a small volume (5mL) of normal saline will be injected to flush the line of remaining anesthetic. The needle will then be withdrawn.
Study NCT06456151 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Invasive candidiasis test
Description: The combination of acute phase marker monitoring and the T2Candida assay will be assessed.
Study NCT06456151 — intervention group
Intervention type: OTHER
Intervention: Urine sample collection for future research
Description: Patients will be asked to provide a urine sample for future research (urine biobank).
Study NCT05467761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Psilocybin
Description: 25mg orally
Study NCT04764591 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lateral sagittal approach
Description: Lateral sagittal approach for ultrasound guided infraclavicular brachial plexus block
Study NCT04764591 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Costoclavicular approach
Description: Costoclavicular approach for ultrasound guided infraclavicular brachial plexus block
Study NCT05467761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Psilocybin
Description: 5mg intravenously
Study NCT05181774 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Proteomics
Description: Proteomic data were obtained by LC-MS/MS Analysis-DIA platform.
Study NCT05181774 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Metabolomics
Description: Metabolomic data were obtained by UPLC-QTOF/MS platform.
Study NCT05912374 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard Community-Friendly Health Recovery Program- Biobehavioral (CHRP-BB)
Description: CHRP-BB is an evidence-informed behavioral intervention for HIV prevention among high-risk drug users in treatment on PrEP. CHRP-BB consists of 4 weekly 50- minute sessions.
Study NCT05912374 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: enhanced Community-Friendly Health Recovery Program- Biobehavioral (CHRP-BB)
Description: The enhanced version of CHRP-BB is an adapted behavioral intervention for HIV prevention among high-risk drug users in treatment on PrEP. This intervention consists of 4 weekly 50- minute sessions that include cognitive dysfunction accommodation strategies.
Study NCT06543797 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: wearable rTMS
Description: Application of inhibitory low-frequency rTMS on unaffected primary motor cortex by wearable rTMS
Study NCT04666831 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted Motivational Interviewing (AMI) and Cognitive Behavioural Therapy (CBT)
Description: The intervention combines AMI techniques as described by Miller and Rollnick (2013) in the third edition of their Motivational Interviewing book, as well as CBT techniques from the Tele-CBT protocol for bariatric surgery patients by Cassin et al. (2013).
Study NCT06350487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitor
Description: Enavogliflozin (0.3mg oral tablet once daily) will be administrated.
Study NCT05732584 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: structured family voice stimulation
Description: The structured family voice stimulation is played to the patients for the first five days after admission to eicu until transfer out or death. The content of the recording is developed according to the structured script.
Study NCT05732584 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: unstructured family voice stimulation
Description: The unstructured family voice stimulation is played to the patients for the first five days after admission to eicu until transfer out or death.
Study NCT06494943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: PD-1 inhibitor
Study NCT06399068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-387
Description: 1 Tablet
Study NCT06399068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D484
Description: 1 Tablet
Study NCT06494943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI110
Description: LAG-3 inhibitor
Study NCT06494943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Chemotherapy
Study NCT06494943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cis Platinum
Description: Chemotherapy
Study NCT06494943 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Definitive surgery
Study NCT06494943 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adjuvant radiation
Description: Adjuvant radiotherapy or chemoradiotherapy based on post-operative pathologic findings.
Study NCT05993585 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Of The Frank Starling Mechanism - Adjustment Of Av Delay And Measurement Of Pre-load -Control
Description: (Control Group): One test of the Starling mechanism Visit 1: Sign consent form, doctor assessment, electrocardiogram (ECG), Starling Test. If patients are in this category, this will be their only research visit
Study NCT05993585 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Other: Test Of The Frank Starling Mechanism - Adjustment Of Av Delay And Measurement Of Pre-load -CRT
Description: (CRT Group): Two tests of the Starling mechanisms Visit 1: Sign consent form, assessment by doctor, electrocardiogram (ECG), Test of the Starling mechanism Visit 2: CRT upgrade procedure - your Cardiologist will explain this procedure to you. Visit 3: CRT pacing check at 6 weeks post-procedure Visit 4: Assessment by doctor, ECG, Echocardiogram, Test of the Starling mechanism at 6 months post-procedure.
Study NCT04741867 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Patients will be educated to determine their level of coping with stress and their adaptation.
Study NCT04670042 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SPRINT® Peripheral Nerve Stimulation (PNS) System (510k Cleared)
Description: Same as Arm Description.
Study NCT04952116 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Eyelid reconstruction
Description: Assessment of differrent techniques in anterior and posterior lamella reconstruction after periocular defects
Study NCT06246019 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Early adoption of blood-based biomarkers for Alzheimer's disease
Description: A blood test will be performed to obtain plasma measures of Amyloid-β (Aβ) 42/40, phosphorylated tau (p-tau) 181, p-tau217, p-tau231 and Glial fibrillary acidic protein (GFAP) and Neurofilament light chain (NfL) and results will be disclosure to the early and late arms at different time points.
Study NCT05192018 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early reversal of a defunctiong ileostomy
Description: Early reversal of a defunctiong ileostomy after 3 weeks of its creation
Study NCT05192018 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Early reversal of a defunctiong ileostomy
Description: Early reversal of a defunctiong ileostomy after 3 weeks of its creation
Study NCT05154617 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Standard surgical monitoring, along with the Flo Trac® system monitoring.
Description: Under standard thoracic anesthesia protocol, extra monitoring will be done by FloTrac® System using a minimally invasive sensor in combination with an advanced monitoring device to derive cardiac output (CO) and cardiac index (CI) parameters through arterial pulse pressure waveform analysis. Intraoperative blood gases collection will be at different intraoperative times. From this data, calculations will be performed to obtain DO2, DO2i, O2ER, and O2ERi.
Study NCT05986968 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Ticagrelor monotherapy for 12 months
Study NCT05986968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Ticagrelor monotherapy for 12 months
Study NCT05986968 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Dual antiplatelet therapy (aspirin plus ticagrelor) for 12 months
Study NCT04881929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN026
Description: KN026 in Combination With Docetaxel
Study NCT04243902 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fill and Flush Valve
Description: The fill and flush valve (Figure 1) is an automated valve which is designed to open in response to rising bladder pressure which occurs as the bladder becomes full. The valve is situated between the IDC and the drainage bag as a manual valve would be.~There are three variants of the valve which respond to different degrees of bladder pressure. People's bladders function at different pressure levels. One of the aims of this study is to gain preliminary data on which valve variant works and under which circumstances. Pressure ranges are as follows:~Low: 22 - 49cm H2O Medium: 35 - 61cm H2O High: 53 - 79cm H2O
Study NCT05173441 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human COVID-19 immunoglobulin (pH4) for intravenous injection
Description: The initial infusion rate is 0.01 \~ 0.02 ml/kg body weight/minute (1ml is about 20 drops). If there was no adverse reaction after 15 minutes, the infusion rate could be gradually accelerated. However, it should not exceed 0.08 ml/kg body weight/minute.
Study NCT05173441 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The initial infusion rate is 0.01 \~ 0.02 ml/kg body weight/minute (1ml is about 20 drops). If there was no adverse reaction after 15 minutes, the infusion rate could be gradually accelerated. However, it should not exceed 0.08 ml/kg body weight/minute
Study NCT04648696 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin CI
Description: The CI group will have their total daily cumulative dose of vancomycin converted to a 24-hour intravenous infusion upon discharge - the CI will begin with the first scheduled OPAT dose of vancomycin
Study NCT04648696 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin II
Description: Study candidates that are randomized to the II group will continue their current intravenous dosing upon discharge
Study NCT05189834 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Gelsectan
Description: Xyloglucan, vegetable protein and xylooligosaccharides
Study NCT05446792 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PFMT
Description: The PFMT will consist of 10 maximum voluntary contractions that must be maintained for at least 6 seconds. Participants will be encouraged to sustain the maximum contraction for a longer time each week. The interval time between contractions will be the same seconds as the contraction. Participants will perform 4 sets of 10 contractions, and at the end of each set of 10 contractions, five fast contractions will be performed. Each series will be performed in one position: lying in lateral decubitus; seated; on all fours and standing.
Study NCT05446792 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PE
Description: The PE group will be instructed and reminded to voluntarily contract the PFMs during each repetition of the Pilates strengthening exercises. During the stretching exercises, the participant will be instructed not to perform the contraction.~The stretching and strengthening exercises will be performed in a single series of 10 repetitions, totaling 10 exercises aimed at the main muscle groups.
Study NCT05179603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THOR-707
Description: Pharmaceutical Form: Solution for infusion Route of Administration: Intravenous infusion
Study NCT05671211 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Task-Oriented Training
Description: Participants in this group will receive 30 minutes of task-oriented training and 1 hour of conventional therapy for 6 weeks 5 times a week.
Study NCT05671211 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Therapy
Description: Conventional therapy will be consisted of balance,upper and lower extremity strengthening exercises.
Study NCT05533450 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multi-focal rigid scleral contact lens
Description: True scleral lenses rest on the sclera and do not touch the cornea and limbus, leaving a clear area between the contact lens and the cornea.
Study NCT05533450 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rigid gas permeable contact lens
Description: RGP contact lens is designed from a special rigid hydrophobic material. Patients wear RGP contact lens to form a contact lens-tear-cornea system to correct irregular astigmatism, reduce aberrations, provide good visual quality, and control the development of the disease through mild shaping effect.
Study NCT06159959 — intervention group
Intervention type: DRUG
Intervention: Carbetocin
Description: To assess the effectiveness of single IV bolus dose of carbetocin in the prevention of primary PPH in obese versus non obese women undergoing elective cesarean section.
Study NCT06397196 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laser guided proprioceptive exercises
Description: Participants will receive Laser guided Proprioceptive exercises on alternate days (3 days a week) for 3 weeks. Total number of sessions will be 9
Study NCT06397196 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine Physical therapy
Description: Participants will receive routine physical therapy on alternate days (3 days a week) for 3 weeks. Total number of sessions will be 9
Study NCT06397196 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Physical therapy
Description: Participants will receive routine physical therapy on alternate days (3 days a week) for 3 weeks. Total number of sessions will be 9
Study NCT05698225 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Streptococcus pneumoniae serotype 6B
Description: A controlled concentration of streptococcus pneumoniae serotype 6B is placed in both nares of participants
Study NCT05179603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pharmaceutical Form: Solution for infusion Route of Administration: Intravenous infusion
Study NCT06052826 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Undergo standard of care
Study NCT06052826 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Intervention
Description: Receive delirium prevention education
Study NCT06052826 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive Geriatric Assessment
Description: Undergo geriatric assessment
Study NCT06052826 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional Intervention
Description: Undergo nutritional optimization
Study NCT06052826 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Undergo physical function optimization
Study NCT06052826 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies